Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on May 20, 2025
Altais and Autonomize AI Partner to Reduce Administrative Burden and Empower Clinical Teams
GlobeNewswire
·
May 20, 2025
AUSTIN, Texas, and OAKLAND, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Altais and Autonomize AI today announced a strategic partnership aimed at reducing the rising administrative burden on care management and clinical quality teams. Altais will introduce …
Health Catalyst to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SALT LAKE CITY, May 20, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial …
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
Marine Biologics Expands Leadership Team to Drive Next Phase of Growth
GlobeNewswire
·
May 20, 2025
BERKELEY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today introduced Danièle Karleskind, Ph.D. as its new Chief Operations Officer and Ryan Hunt as Director of Business Development. With more than 55 years of combined …
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire
·
May 20, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent …
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewswire
·
May 20, 2025
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
GlobeNewswire
·
May 20, 2025
• Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“ …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
GlobeNewswire
·
May 20, 2025
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal …
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
GlobeNewswire
·
May 20, 2025
NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of combination drug therapies, today announced …
BriaCell CEO Letter to Shareholders
GlobeNewswire
·
May 20, 2025
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitor Bria-IMT has received Fast Track designation from FDA and patient enrollment …
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
GlobeNewswire
·
May 20, 2025
TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities …
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
GlobeNewswire
·
May 20, 2025
– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first …
Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
GlobeNewswire
·
May 20, 2025
Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was well-tolerated and patients were able to be discharged within …
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 20, 2025
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings …
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
GlobeNewswire
·
May 20, 2025
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an …